Literature DB >> 6704043

Facioscapulohumeral muscular dystrophy and accompanying hearing loss.

M D Meyerson, E Lewis, K Ill.   

Abstract

Facioscapulohumeral (FSH) muscular dystrophy (MD) is an autosomal dominant condition marked by muscle weakness primarily in the face, shoulder girdle, and legs. Intelligence and life span are normal and the spectrum of disability is broad. Flaccid dysarthria results from the facial muscle paralysis. A pair of siblings had FSH MD that was accompanied by the unusual finding of sensorineural hearing loss. Speech and audiologic aspects are presented and etiologic explanations are suggested. Careful audiologic evaluation of all patients with FSH MD is advised so that sensorineural hearing loss can be ruled out.

Entities:  

Mesh:

Year:  1984        PMID: 6704043     DOI: 10.1001/archotol.1984.00800300053012

Source DB:  PubMed          Journal:  Arch Otolaryngol        ISSN: 0003-9977


  5 in total

Review 1.  A role for epigenetics in hearing: Establishment and maintenance of auditory specific gene expression patterns.

Authors:  Matthew J Provenzano; Frederick E Domann
Journal:  Hear Res       Date:  2007-07-19       Impact factor: 3.208

Review 2.  Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases.

Authors:  Craig M McDonald
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

3.  Hearing loss in facioscapulohumeral dystrophy.

Authors:  T Voit; A Lamprecht; H G Lenard; H H Goebel
Journal:  Eur J Pediatr       Date:  1986-09       Impact factor: 3.183

4.  De novo facioscapulohumeral muscular dystrophy defined by DNA probe p13E-11 (D4F104S1).

Authors:  P E Jardine; M C Koch; P W Lunt; J Maynard; K D Bathke; P S Harper; M Upadhyaya
Journal:  Arch Dis Child       Date:  1994-09       Impact factor: 3.791

5.  Severe visual loss associated with retinal telangiectasis and facioscapulohumeral muscular dystrophy.

Authors:  D Pauleikhoff; N Bornfeld; A C Bird; A Wessing
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.